Baseline circulating tumor DNA (ctDNA) biomarker analysis of patients with human epidermal growth factor receptor 2 (HER2)-overexpressing metastatic non-small cell lung cancer (NSCLC) treated with trastuzumab deruxtecan (T-DXd)

被引：0
|
作者：
Smit, E. F. [1 ]
Felip, E. [2 ]
Uprety, D. [3 ]
Nagasaka, M. [4 ]
Nakagawa, K. [5 ]
Paz-Ares, L. [6 ]
Pacheco, J. [7 ]
Li, B. T. [8 ]
Planchard, D. [9 ]
Baik, C. S. [10 ]
Goto, Y. [11 ]
Murakami, H. [12 ]
Pereira, K. M. C. [13 ]
Taguchi, A. [14 ]
Kogo, M. [14 ]
Kuwahara, Y. [13 ]
Zou, M. [13 ]
Feng, W. [13 ]
Tsuchihashi, Z. [13 ]
Janne, P. A. [15 ]
机构：
[1] Univ Med Ctr, Dept Pulm Dis, Leiden, Netherlands
[2] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Barcelona, Spain
[3] Barbara Ann Karmanos Canc Inst, Med Oncol, Detroit, MI USA
[4] Univ Calif Irvine, Sch Med, Med, Orange, CA USA
[5] Kindai Univ Hosp, Med Oncol, Osaka, Japan
[6] Clin Univ Navarra, Med Oncol, Madrid, Spain
[7] Univ Colorado, Ctr Canc, Internal Med, Med Oncol, Aurora, IL USA
[8] Mem Sloan Kettering Canc Ctr, Med, New York, NY USA
[9] Gustave Roussy, Med Oncol, Villejuif, France
[10] Univ Washington, Med Oncol, Seattle, WA USA
[11] Natl Canc Ctr, Thorac Oncol Dept, Tokyo, Japan
[12] Shizuoka Canc Ctr, Med Oncol, Shizuoka, Japan
[13] Daiichi Sankyo Inc, Oncol, Basking Ridge, NJ USA
[14] Daiichi Sankyo Co Ltd, Oncol, Tokyo, Japan
[15] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2875
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
151P
引用
收藏
页码：S241 / S242
页数：2
相关论文
共 50 条
  • [1] Trastuzumab deruxtecan in HER2 overexpressing non-small cell lung cancer (NSCLC)
    Pitiyarachchi, Omali
    Tan, Aaron C.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2025, 14 (02)
  • [2] Population pharmacokinetics of trastuzumab deruxtecan (T-DXd) in subjects with HER2-mutant and HER2-overexpressing non-small cell lung cancer (NSCLC)
    Khatri, Amit
    Cobbina, Enoch
    Cheng, Shen
    Abutarif, Malaz
    Garimella, Tushar
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [3] Spotlight on Trastuzumab Deruxtecan (DS-8201, T-DXd) for HER2 Mutation Positive Non-Small Cell Lung Cancer
    Azar, Ibrahim
    Alkassis, Samer
    Fukui, Jami
    Alsawah, Fares
    Fedak, Kalub
    Al Hallak, Mohammed Najeeb
    Sukari, Ammar
    Nagasaka, Misako
    LUNG CANCER-TARGETS AND THERAPY, 2021, 12 : 103 - 114
  • [4] Trastuzumab deruxtecan (T-DXd) in Asian patients (Pts) with human epidermal growth factor receptor 2 (HER2; ERBB2)mutant (HER2m) metastatic non-small cell lung cancer (mNSCLC): Subgroup analysis of DESTINYeLung02 (DL-02)
    Goto, Y.
    Goto, K.
    Kubo, T.
    Ninomiya, K.
    Kim, S-W.
    Ahn, M-J.
    Nakagawa, K.
    Hayashi, H.
    Shimizu, J.
    Kim, D-W.
    Yang, J. C-H.
    Kuo, C-H. S.
    Lee, K. H.
    Yang, T-Y.
    Pereira, K. M. C.
    Taguchi, A.
    Ali, A.
    Cheng, F-C.
    Yonemochi, R.
    Janne, P. A.
    ANNALS OF ONCOLOGY, 2023, 34 : S1666 - S1667
  • [5] Impact of Serum HER2 Extracellular Domain in Metastatic Breast Cancer Patients Treated with Trastuzumab Deruxtecan (T-DXd)
    Nozawa, Kazuki
    Kusudo, Maho
    Kureyama, Nari
    Nakakami, Akira
    Komaki, Rie
    Endo, Yuka
    Kataoka, Ayumi
    Kotani, Haruru
    Yoshimura, Akiyo
    Hattori, Masaya
    Sawaki, Masataka
    Iwata, Hiroji
    CANCER RESEARCH, 2024, 84 (09)
  • [6] Valemetostat and trastuzumab deruxtecan (T-DXd) in previously treated advanced or metastatic human epidermal growth factor receptor 2 (HER2)-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma
    Shitara, K.
    Enzinger, P. C.
    Mohapatra, A. S.
    Janjigian, Y. Y.
    ANNALS OF ONCOLOGY, 2024, 35 : S200 - S200
  • [7] Trastuzumab deruxtecan (T-DXd) in patients with HER2-mutant metastatic non-small cell lung cancer (mNSCLC): Final analysis results of DESTINY-Lung02.
    Janne, Pasi A.
    Goto, Yasushi
    Kubo, Toshio
    Ninomiya, Kiichiro
    Kim, Sang-We
    Planchard, David
    Ahn, Myung-Ju
    Smit, Egbert F.
    De langen, Adrianus Johannes
    Perol, Maurice
    Pons-Tostivint, Elvire
    Novello, Silvia
    Hayashi, Hidetoshi
    Shimizu, Junichi
    Kim, Dong-Wan
    Pereira, Kaline
    Cheng, Fu-Chih
    Taguchi, Ayumi
    Cheng, Yingkai
    Goto, Koichi
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [8] Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-mutated metastatic non-small cell lung cancer (NSCLC): Interim results of DESTINY-Lung01.
    Smit, Egbert F.
    Nakagawa, Kazuhiko
    Nagasaka, Misako
    Felip, Enriqueta
    Goto, Yasushi
    Li, Bob T.
    Pacheco, Jose Maria
    Murakami, Haruyasu
    Barlesi, Fabrice
    Saltos, Andreas Nicholas
    Perol, Maurice
    Udagawa, Hibiki
    Saxena, Kapil
    Shiga, Ryota
    Guevara, Ferdinand M.
    Acharyya, Suddhasatta
    Shahidi, Javad
    Planchard, David
    Janne, Pasi A.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [9] Valemetostat and trastuzumab deruxtecan (T-DXd) in previously treated advanced or metastatic human epidermal growth factor receptor 2 (HER2)-positive gastric cancer or gastro-esophageal junction (GEJ) adenocarcinoma.
    Shitara, Kohei
    Enzinger, Peter C.
    Mohapatra, Avani
    Janjigian, Yelena Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : TPS508 - TPS508
  • [10] Trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutant metastatic non-small cell lung cancer (NSCLC): Interim results from the phase 2 DESTINY-Lung02 trial
    Goto, K.
    Sang-We, K.
    Kubo, T.
    Goto, Y.
    Ahn, M-J.
    Planchard, D.
    Kim, D-W.
    Yang, J. C-H.
    Yang, T-Y.
    Pereira, K. M. C.
    Saxena, K.
    Shiga, R.
    Cheng, Y.
    Aregay, M.
    Janne, P. A.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1422 - S1422
12345